Biotech Investments on the Upswing - Keryx and ADVENTRX Poised to Benefit
February 23 2012 - 8:20AM
Marketwired
Biotechnology stocks have performed well of late as companies from
across the globe earn more investments. According to a report from
Boulder-based data company OnBioVC, biotech companies attracted
close to double the amount of investment in the fourth quarter of
2011 than they did in the same period of 2010. The Paragon Report
examines investing opportunities in the Biotechnology Industry and
provides equity research on Keryx Biopharmaceuticals Inc. (NASDAQ:
KERX) & ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX). Access
to the full company reports can be found at:
www.paragonreport.com/KERX
www.paragonreport.com/ANX
According to BIO Industry Analysis survey data, there is renewed
optimism surrounding the biotechnology industry among investors
amid signs that FDA approvals may be on the rise in 2012. "The BIO
CEO & Investor Conference synthesized the overall mood within
the industry of momentum and progress with recent approvals and
increased M&A activity, and optimism for the year ahead," said
Alan Eisenberg, executive vice president of Emerging Companies and
Business Development at BIO.
The BIO survey shows that 56 percent of investors think now is a
good time to invest -- specifically with early stage companies and
those focused on autoimmune disease and oncology.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the biotechnology industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Biotech stocks have been on an impressive upswing this year,
handedly outperforming the broader market. The SPDR S&P Biotech
ETF (XBI) -- which holds an equal amount of large companies as well
as small companies, translating to increased risks and potentially
higher rewards -- is up more than 15 percent year to date.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company,
together with its subsidiaries, focuses on the acquisition,
development, and commercialization of pharmaceutical products for
the treatment cancer and renal disease.
ADVENTRX Pharmaceuticals, Inc., specialty pharmaceutical
company, focuses on acquiring, developing, and commercializing
proprietary product candidates.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Adventrx (AMEX:ANX)
Historical Stock Chart
From May 2024 to Jun 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2023 to Jun 2024